Status:
UNKNOWN
NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
In type 2 diabetics, progression from chronic kidney disease to end stage renal disease may be slowed down by therapeutic interventions as angiotensin converting enzyme inhibitors use, control of high...
Eligibility Criteria
Inclusion
- Type 2 diabetes. Age between 18 and 80 years, male or female. Cockcroft's clearance between 25 and 60 ml / min. Haemoglobin level superior to 100 g/L and strictly inferior to 130 g/L
Exclusion
- Malignancy Solid organ transplant Acute pathology in the two months before inclusion date Myocardial infarction, stroke, pulmonary embolism in the six months before inclusion date Contra-indication to martial treatment or EPO treatment Present inclusion in another clinical study Patient who cannot answer questions of SF36 questionnaire
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00279084
Start Date
January 1 2004
Last Update
October 4 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Joëlle Gillet
Lyon, France, 69376